Skip to Content

View Additional Section Content

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RG-012 for Injection Administered Every 2 Weeks in Patients with Alport Syndrome

Clinical Trial Categories

  • Alport Syndrome
Contact
Renee Backer, CCRC at 215-361-7164
or research@greenandseidner.com

Location

  • Green and Seidner Family Practice Associates, PC
    826 North Broad Street
    Lansdale, PA 19446
    Office: 215-855-1054
    Fax: 215-855-3786

Find a Physician
Search Our Directory

215-481-MEDI

Schedule a
Test

215-481-EXAM